All In Biotech

Drug Trial Radar · NCT06311734

A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

A Single-center, Randomized, Double-blind,Placebo-controlled Study, to Evaluate Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of LW231 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

Jun 21, 2022

Primary completion

Jan 1, 2024

Study completion Mar 18, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To Evaluate the Tolerability and Pharmacokinetics of LW231 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects .

Conditions

  • Chronic Hepatitis B

Interventions

  • LW231 tabletsDrug

    P.O.

  • PlaceboDrug

    P.O.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Up to 4 days for SAD, up to 3 days after the last dose of study drug for MAD

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.